Skip to content

Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia

Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02940080
Enrollment
18
Registered
2016-10-20
Start date
2016-10-31
Completion date
2021-12-31
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Glycemia

Brief summary

A randomized, single-blind cross-over clinical nutrition trial will be conducted. The effects of yellow-fleshed potatoes and yellow-fleshed potatoes supplemented with anthocyanins extracted from purple-fleshed potatoes on healthy men's postprandial glycemia and insulinemia will be compared. Additionally, the postprandial metabolism and metabolites, and the appearance and metabolism of the flavonoids and their metabolites is studied in plasma, urine and feces.

Interventions

OTHERDietary

Sponsors

University of Turku
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-45 * Male * No regular medication * No participation in a drug trial or blood donation within 2 months * Non-smoker * Signs informed consent * Body mass index 18.5-27 kg/m2 * Fasting plasma cholesterol \< 5.5 mmol/l * Fasting plasma triacylglycerols \< 2.6 mmol/l * Fasting plasma glucose 4-6 mmol/l * blood pressure \<140/80 mmHg * hemoglobin\>130 g/l * Fasting plasma alanine amino transferase (ALAT) \<60 U/l (normal liver function) * Fasting plasma thyroid-stimulating hormone (TSH) 0.4 - 4.5 mU/l (normal thyroid function) * Fasting plasma creatinine \<118 µmol/l (normal kidney function)

Exclusion criteria

* Regular smoking * Alcohol abuse * Regular medication

Design outcomes

Primary

MeasureTime frame
Plasma glucose concentration0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Plasma insulin concentration0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min

Secondary

MeasureTime frame
Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in plasma (NMR and (U)HPLC-MS/MS measurements)0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in urine (NMR and (U)HPLC-MS/MS measurements)Before meal, and 0-4h, 4-8h, 8-16h, 16-24 h
Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in feces (NMR and (U)HPLC-MS/MS measurements)before and after meal
Area under the glucose concentration curve (AUC)0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Area under the insulin concentration curve (AUC)0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026